Fertility warning
This medicine may affect fertility.
Leaflet ZEGOMIB 3.5mg powder for solution for injection
- Product code:
- W61993002
- Quantity:
- 3
- Indicated for:
- multiple myeloma
- Route of administration:
- injectable
- Substance:
- bortezomib (proteasome inhibitor)
- ATC
- L01XX32 — Antineoplastic and immunomodulating agents | Other antineoplastic agents
Precautions:
Cytotoxic / special handling
Handle with special care.
Contraception required
Effective contraception is required during treatment.
Contraindicated during breastfeeding
Do not use this medicine while breastfeeding.
Contraindicated during pregnancy
Do not use this medicine during pregnancy.
Hepatotoxicity
This medicine may affect the liver.
Major drug interactions
This medicine may have important interactions with other medicines.
Myelosuppression / agranulocytosis
This medicine may lower blood cell counts.
Additional monitoring
This medicine is subject to additional monitoring.
Requires periodic laboratory tests
Periodic laboratory tests may be required during treatment.
Neuropathy / neurotoxicity
This medicine may affect the nerves or nervous system.
Severe skin reactions
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Bortezomib is a medication used for the treatment of multiple myeloma and mantle cell lymphoma. It is a proteasome inhibitor that interferes with essential cellular processes in cancer cells, leading to their death.
The medication is administered via subcutaneous or intravenous injection, usually in treatment cycles, as directed by a doctor. The dosage and duration of treatment are adjusted based on the patient's condition and response to therapy.
Common side effects include fatigue, nausea, diarrhea, peripheral neuropathy, and decreased blood cell counts. In rare cases, more severe adverse effects such as heart failure or pulmonary toxicity may occur.
Bortezomib is not recommended for pregnant or breastfeeding women, as it may affect fetal development. Patients should inform their doctor about all medications they are taking to avoid drug interactions.
The medication is administered via subcutaneous or intravenous injection, usually in treatment cycles, as directed by a doctor. The dosage and duration of treatment are adjusted based on the patient's condition and response to therapy.
Common side effects include fatigue, nausea, diarrhea, peripheral neuropathy, and decreased blood cell counts. In rare cases, more severe adverse effects such as heart failure or pulmonary toxicity may occur.
Bortezomib is not recommended for pregnant or breastfeeding women, as it may affect fetal development. Patients should inform their doctor about all medications they are taking to avoid drug interactions.
General data about ZEGOMIB 3.5mg
- Substance:
- bortezomib
- Date of latest medicines list:
- 01-03-2021
- Product code:
- W61993002
- Concentration:
- 3.5mg
- Pharmaceutical form:
- powder for solution for injection
- Quantity:
- 3
- Product type:
- Generic medicine
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for bortezomib
Concentrations available for bortezomib
- 1mg
- 2.5mg
- 2.5mg/ml
- 25mg/ml
- 3.5mg